Regeneron Pharmaceuticals is presenting 36 abstracts at the AAAAI26 conference, highlighting their latest advancements in immunology and inflammation research. A significant development includes their first-time Phase 3 presentations for cat and birch allergy treatments. This participation underscores Regeneron’s continued commitment to innovation and progress in the medical field.
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
Regeneron Pharmaceuticals showcases 36 breakthroughs at AAAAI26
Regeneron Pharmaceuticals is presenting 36 abstracts at the AAAAI26 conference, highlighting their latest advancements in immunology and inflammation research. A significant development includes their first-time Phase 3 presentations for cat and birch allergy treatments. This participation underscores Regeneron’s continued commitment to innovation and progress in the medical field.